ГЭН Цзяньго (CN),ЧЭНЬ Мин (CN),ЯН Сяомэй (CN),ЧИ Шань (CN)
申请号：
RU2012151270/15
公开号：
RU2012151270A
申请日:
2011.04.29
申请国别(地区):
RU
年份:
2014
代理人:
摘要：
1. A method for the prophylaxis or treatment of a disorder mediated Slit-protein, comprising: administering to the subject a therapeutically effective amount of an agent that modulates or prevents the interaction between Slit-Robo-protein and protein, wherein the disorder involves the formation of lymph sosudov.2. The method of claim 1, wherein Slit-protein is Slit2.3. The method of claim 1, wherein Robo-protein is Robo1 or Robo4.4. The method of claim 1, wherein the agent is an antibody to Slit-belku.5. The method of claim 1, wherein the agent is an anti-Robo-belku.6. A method according to claim 4 or 5, wherein the antibody is a monoclonal antitelo.7. A method according to claim 6, wherein the antibody is a humanized antitelo.8. The method of claim 1, wherein the agent is a fragment of the extracellular domain of Robo-belka.9. The method of claim 8, wherein the fragment is derived from the first immunoglobulin-like domain Robo-belka.10. The method of claim 1, wherein the agent is a fusion Robo-belok.11. The method of claim 10, wherein the fusion Robo-protein is a fusion protein Robo--Fc.12. A composition for preventing or treating a disorder mediated Slit-protein, comprising: an agent which can modulate the interaction between the protein and Slit-Robo-protein or hinder it and a pharmaceutically acceptable excipient, carrier or diluent, wherein the disorder involves the formation of lymph sosudov.13. A composition according to claim 12, wherein Slit-protein is Slit2.14. A composition according to claim 12, wherein the agent is an antibody to a protein or Slit-Robo-to belku.15. A composition according to claim 14, wherein the antibody is a monoclonal antitelo.16. A composition according to claim 15, wherein the antibody is a humanized anti1. Способ профилактики или лечения расстройства, опосредованного Slit-белком, включающий:введение индивиду терапевтически эффективного количества средства, которое модулирует или предотвращает взаимодействия между Slit-белком и Rob
